Methods In Enzymology Hardcover

0128186739

9780128186732

English

Elsevier Science Publishing Co Inc

29 January 2020

554

Lorenzo Galluzzi (born 1980) is currently an assistant professor of cell biology in radiation oncology at the department of radiation oncology of the Weill Cornell medical college (new york, USA), and honorary associate professor at the faculty of medicine of the Paris Descartes University (Paris, France). Before joining Weill Cornell medical college (2017), Lorenzo Galluzzi was a junior scientist of the research team "apoptosis, cancer and immunity" at the Cordeliers research centre (Paris, France; 2012-2016). Lorenzo Galluzzi did his post-doctoral training at the Gustave Roussy Cancer Center (Villejuif, France; 2009-2011), after receiving his PhD from the Paris sud university (Le Kremlin-Bicetre, France; 2005-2008). He is also associate director of the European academy for tumour immunology (EATI), and founding member of the European research institute for integrated cellular pathology (ERI-ICP). Lorenzo Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumour metabolism and tumour immunology. In particular, he provided profound insights into the links between adaptive stress responses in cancer cells and the activation of a clinically relevant tumour-targeting immune response in the context of chemotherapy and radiation therapy. Lorenzo Galluzzi has published more than 350 scientific articles in international peer-reviewed journals. According to a survey published by lab times, he is currently the 6th and the youngest of the 30 most-cited European cell biologists (relative to the period 2007-2013). Lorenzo Galluzzi currently operates as editor-in-chief of three journals: Oncoimmunology (which he co-founded in 2011), the international review of cell and molecular biology, and molecular and cellular oncology (which he co-founded in 2013). Besides, Lorenzo Galluzzi currently serves as the founding editor for microbial cell and cell stress, and associate editor for cell death and disease. Nils-Petter Rudqvist received his m.Sc. (physics, 2009) and PhD (medical science, 2015) from the University of Gothenburg, Sweden. He decided to pursue an academic career and continue with his postdoctoral training in us. He first joined the centre for radiological research at Columbia university in new york where he studied gene signatures of radiation exposure. He then moved to Weill Cornell medicine to join the program in radiation and immunity under the mentorship of Dr. Demaria. His current research is focused on investigating which neoantigens are key targets of the radiation-induced anti-tumour t cell response in mice and in patients treated with radiotherapy and immune checkpoint blockade. He recently demonstrated in a mouse model that radiation therapy diversifies the TCR repertoire of tumour-infiltrating lymphocytes, an effect crucial for its synergy with immune checkpoint blockade treatment. Nils-petter has also defined unique patters of expansion of TCR clonotypes in patients who respond or not to treatment with radiotherapy and ipilimumab. He has published 20 articles in peer-reviewed scientific journals and 60+ scientific conference abstracts.

Lorenzo Galluzzi

Nils-Petter Rudqvist